Scienture (SCNX) Competitors $8.13 -0.25 (-2.98%) (As of 11:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends SCNX vs. QURE, AVIR, URGN, IMMP, ETON, MRSN, LFCR, LYEL, ATAI, and PGENShould you be buying Scienture stock or one of its competitors? The main competitors of Scienture include uniQure (QURE), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Immutep (IMMP), Eton Pharmaceuticals (ETON), Mersana Therapeutics (MRSN), Lifecore Biomedical (LFCR), Lyell Immunopharma (LYEL), Atai Life Sciences (ATAI), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry. Scienture vs. uniQure Atea Pharmaceuticals UroGen Pharma Immutep Eton Pharmaceuticals Mersana Therapeutics Lifecore Biomedical Lyell Immunopharma Atai Life Sciences Precigen Scienture (NASDAQ:SCNX) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Which has preferable valuation & earnings, SCNX or QURE? Scienture has higher earnings, but lower revenue than uniQure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScienture$8.27M8.43-$17.84MN/AN/AuniQure$15.84M17.57-$308.48M-$4.96-1.15 Is SCNX or QURE more profitable? Scienture has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Scienture's return on equity of -77.60% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets ScientureN/A -77.60% -62.29% uniQure -837.80%-188.82%-32.17% Does the MarketBeat Community prefer SCNX or QURE? uniQure received 645 more outperform votes than Scienture when rated by MarketBeat users. CompanyUnderperformOutperformScientureN/AN/AuniQureOutperform Votes64570.65% Underperform Votes26829.35% Which has more volatility and risk, SCNX or QURE? Scienture has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Does the media favor SCNX or QURE? In the previous week, uniQure had 1 more articles in the media than Scienture. MarketBeat recorded 1 mentions for uniQure and 0 mentions for Scienture. Scienture's average media sentiment score of 0.00 beat uniQure's score of -1.00 indicating that Scienture is being referred to more favorably in the media. Company Overall Sentiment Scienture Neutral uniQure Negative Do insiders and institutionals believe in SCNX or QURE? 5.7% of Scienture shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 29.1% of Scienture shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer SCNX or QURE? uniQure has a consensus price target of $17.00, indicating a potential upside of 197.72%. Given uniQure's stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than Scienture.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00uniQure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryuniQure beats Scienture on 9 of the 15 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Scienture News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNX vs. The Competition Export to ExcelMetricScienturePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.76M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E RatioN/A4.9791.2813.60Price / Sales8.43371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book0.8210.306.906.33Net Income-$17.84M$153.61M$118.83M$225.93M7 Day Performance2.01%-1.73%-1.92%-0.96%1 Month Performance21.34%-7.26%-3.75%1.06%1 Year PerformanceN/A31.10%31.37%26.59% Scienture Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNXScientureN/A$8.13-3.0%N/AN/A$69.76M$8.27M0.00N/AQUREuniQure3.0851 of 5 stars$5.71+0.2%$17.00+197.7%-18.2%$278.31M$15.84M-1.15500News CoverageNegative NewsAVIRAtea Pharmaceuticals2.7626 of 5 stars$3.24+2.5%$6.88+112.3%+5.0%$273.65M$351.37M0.0070URGNUroGen Pharma3.7235 of 5 stars$11.51+0.5%$48.38+320.3%-7.9%$269.91M$82.71M-3.63200IMMPImmutep1.3181 of 5 stars$1.85-5.6%$8.50+359.5%+4.8%$269.10M$5.14M0.002,021ETONEton Pharmaceuticals2.9126 of 5 stars$10.39-0.4%$13.00+25.1%+202.8%$268.48M$31.64M0.0020Short Interest ↓Analyst RevisionMRSNMersana Therapeutics4.3672 of 5 stars$2.17-2.3%$6.00+176.5%+38.8%$268.06M$36.85M-3.57150Analyst RevisionLFCRLifecore Biomedical1.5431 of 5 stars$7.26-2.9%$8.00+10.2%+0.7%$267.39M$128.26M93.50690LYELLyell Immunopharma0.4947 of 5 stars$0.95-7.4%$1.00+4.8%-46.9%$266.35M$130,000.00-1.30270ATAIAtai Life Sciences2.3842 of 5 stars$1.54-3.1%$9.00+484.4%+42.0%$258.41M$310,000.000.0083Analyst ForecastAnalyst RevisionPGENPrecigen3.7724 of 5 stars$0.87+4.4%$7.00+701.0%-30.9%$255.94M$6.22M0.00202Analyst Revision Related Companies and Tools Related Companies QURE Competitors AVIR Competitors URGN Competitors IMMP Competitors ETON Competitors MRSN Competitors LFCR Competitors LYEL Competitors ATAI Competitors PGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCNX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCNX Stock Alerts